China Sky One Medical (CSKI) Obtains Production License Renewal for Sumei Slim Patch
More News related to CSKI
- China Sky One Medical, Inc. Reports Outcome of Annual Meeting of Shareholders
- Newsletter Says Sell China Sky One Medical (CSKI)
- China Sky One Medical (CSKI) Begins Export of its Pain Relief Patch to Canada
- China Sky One Medical (CSKI) Submits Application to Perform Clinical Trials for Two New Eye Drugs to SFDA
- China Sky One Medical (CSKI) Up On Newsletter Recommendation
More News related to FDA
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
China Sky One Medical, Inc. (Nasdaq: CSKI) announced that it obtained a renewal of its license for the production its proprietary Sumei Slim Patch from Heilongjiang Provincial FDA, which will be effective through April of 2013. Categorized as a medical device, the document number for the renewed SFDA approval of the Sumei Slim Patch is 2640029.
The Sumei Slim Patch is one of China Sky One Medical's best selling products, accounting for 22% of total revenues in 2008. It is marketed and sold as a natural way to lose weight and has been shown to be 76.9% effective in clinical trials.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.19Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
